Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Ritchie

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
British Journal of Haematology|June 4, 2020
A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variabilityLucy C Fox, Michelle Tan, Anna L Brown, et al.
Oncoimmunology|June 17, 2022
Intratumoural administration of an NKT cell agonist with CpG promotes NKT cell infiltration associated with an enhanced antitumour response and abscopal effectKef K Prasit, Laura Ferrer-Font, Olivia K Burn, et al.
Haematologica|May 20, 2021
Myeloma natural killer cells are exhausted and have impaired regulation of activationCriselle D'Souza, Simon P Keam, Han Xian Aw Yeang, et al.
Immunity|January 23, 2016
Diversity of T Cells Restricted by the MHC Class I-Related Molecule MR1 Facilitates Differential Antigen RecognitionNicholas A Gherardin, Andrew N Keller, Rachel E Woolley, et al.
Scientific Reports|March 9, 2018
Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myelomaNicholas A Gherardin, Liyen Loh, Lorenztino Admojo, et al.
Immunology and Cell Biology|February 14, 2018
Human blood MAIT cell subsets defined using MR1 tetramersNicholas A Gherardin, Michael Nt Souter, Hui-Fern Koay, et al.
The New England Journal of Medicine|June 13, 2025
Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and CyclosporinDavid J Curtis, Sushrut S Patil, John Reynolds, et al.
Haematologica|June 30, 2022
The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cellsKelden Richardson, Simon P Keam, Joe Jiang Zhu, et al.
Leukemia & Lymphoma|September 25, 2014
A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemiaSimon Z He, Samantha Busfield, David S Ritchie, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 9, 2013
Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemiaDavid S Ritchie, Paul J Neeson, Amit Khot, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
British Journal of Haematology|June 4, 2020
A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variabilityLucy C Fox, Michelle Tan, Anna L Brown, et al.
Oncoimmunology|June 17, 2022
Intratumoural administration of an NKT cell agonist with CpG promotes NKT cell infiltration associated with an enhanced antitumour response and abscopal effectKef K Prasit, Laura Ferrer-Font, Olivia K Burn, et al.
Haematologica|May 20, 2021
Myeloma natural killer cells are exhausted and have impaired regulation of activationCriselle D'Souza, Simon P Keam, Han Xian Aw Yeang, et al.
Immunity|January 23, 2016
Diversity of T Cells Restricted by the MHC Class I-Related Molecule MR1 Facilitates Differential Antigen RecognitionNicholas A Gherardin, Andrew N Keller, Rachel E Woolley, et al.
Scientific Reports|March 9, 2018
Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myelomaNicholas A Gherardin, Liyen Loh, Lorenztino Admojo, et al.
Immunology and Cell Biology|February 14, 2018
Human blood MAIT cell subsets defined using MR1 tetramersNicholas A Gherardin, Michael Nt Souter, Hui-Fern Koay, et al.
The New England Journal of Medicine|June 13, 2025
Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and CyclosporinDavid J Curtis, Sushrut S Patil, John Reynolds, et al.
Haematologica|June 30, 2022
The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cellsKelden Richardson, Simon P Keam, Joe Jiang Zhu, et al.
Leukemia & Lymphoma|September 25, 2014
A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemiaSimon Z He, Samantha Busfield, David S Ritchie, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 9, 2013
Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemiaDavid S Ritchie, Paul J Neeson, Amit Khot, et al.
Pageof 10